RCMU
SGMO

Rokos Capital Management (UK)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Rokos Capital Management (UK)’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,474,348
Closed -$3.94M – 113
2023
Q3 		$3.94M Hold
6,474,348
– – 0.03% 88
2023
Q2 		$8.06M Hold
6,474,348
– – 0.08% 59
2023
Q1 		$11.4M Buy
6,474,348
+3,448,138
+114% +$9.84M 0.84% 26
2022
Q4 		$9.15M Hold
3,026,210
– – 0.4% 33
2022
Q3 		$15.4M Hold
3,026,210
– – 0.46% 44
2022
Q2 		$12.5M Buy
3,026,210
+2,048,547
+210% +$8.86M 0.37% 48
2022
Q1 		$5.86M Buy
977,663
+437,803
+81% +$2.6M 0.27% 44
2021
Q4 		$4.11M Hold
539,860
– – 0.25% 25
2021
Q3 		$4.95M Buy
+539,860
New +$5.34M 0.11% 45

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rokos Capital Management (UK)'s SGMO Position: Q4 2023 in Review

Rokos Capital Management (UK) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 6,474,348 shares — an estimated $3.94M sold.

Rokos Capital Management (UK) first reported a position in SGMO in Q3 2021 and held it in 9 quarters. The position peaked at $15.4M in Q3 2022. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Rokos Capital Management (UK) reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Rokos Capital Management (UK) sold 6,474,348 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $3.94M.
  • Rokos Capital Management (UK) first reported a position in SANGAMO THERAPEUTICS INC in Q3 2021 and held it in 9 quarters.
  • Rokos Capital Management (UK)'s SANGAMO THERAPEUTICS INC position peaked at $15.4M in Q3 2022.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Rokos Capital Management (UK)'s 13F filing for Q4 2023, filed 14 Feb 2024.